Association of Single Nucleotide Polymorphisms in Nucleotide-Binding Domain Leucine-Rich Repeat Protein 1 with Clostridioides difficile Colonization or Infection

References

• Hung YP, Tsai CS, Tsai BY., et al. Clostridioides difficile infection in patients with hematological malignancy: a multicenter study in Taiwan. J Microbiol Immunol Infect. 2021;54(6):1101–1110. doi:10.1016/j.jmii.2021.02.002
   PubMedGoogle Scholar
• Chiu CW, Tsai PJ, Lee CC, Ko WC, Hung YP. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - a possibility or an improbability? J Microbiol Immunol Infect. 2021;54(6):1011–1017. doi:10.1016/j.jmii.2021.06.002
   PubMedGoogle Scholar
• Lee CC, Lee JC, Chiu CW, Tsai PJ, Ko WC, Hung YP. Clinical significance of toxigenic clostridioides difficile growth in stool cultures during the era of nonculture methods for the diagnosis of C. difficile infection. Microbiol Spectr. 2021;9(2):e0079921. doi:10.1128/Spectrum.00799-21
   PubMed Web of Science ®Google Scholar
• Tsai CS, Cheng YL, Chen JS, et al. Hypervirulent Clostridioides difficile RT078 lineage isolates from the river: a potential reservoir for environmental transmission. J Microbiol Immunol Infect. 2022;55(5):977–981. doi:10.1016/j.jmii.2022.05.002
   PubMedGoogle Scholar
• Tsai BY, Chien CC, Huang SH, et al. The emergence of Clostridioides difficile PCR ribotype 127 at a hospital in northeastern Taiwan. J Microbiol Immunol Infect. 2022;55(5):896–909. doi:10.1016/j.jmii.2021.12.006
   PubMedGoogle Scholar
• Zhang RF, Man YX, Bai YY, et al. Molecular characterization of Clostridioides difficile ribotype 027 in a major Chinese hospital. J Microbiol Immunol Infect. 2021;54(6):1179–1183. doi:10.1016/j.jmii.2021.01.003
   PubMedGoogle Scholar
• Lee JC, Hung YP, Tsai BY, Tsai PJ, Ko WC. Severe Clostridium difficile infections in intensive care units: diverse clinical presentations. J Microbiol Immunol Infect. 2021;54(6):1111–1117. doi:10.1016/j.jmii.2020.07.012
   PubMedGoogle Scholar
• Hung YP, Lee JC, Tsai BY, et al. Risk factors of Clostridium difficile-associated diarrhea in hospitalized adults: vary by hospitalized duration. J Microbiol Immunol Infect. 2021;54(2):276–283. doi:10.1016/j.jmii.2019.07.004
   PubMedGoogle Scholar
• Lai YH, Tsai BY, Hsu CY, et al. The role of toll-like receptor-2 in Clostridioides difficile Infection: evidence from a mouse model and clinical patients. Front Immunol. 2021;12:691039. doi:10.3389/fimmu.2021.691039
   PubMed Web of Science ®Google Scholar
• DuPont HL, Garey K, Caeiro JP, Jiang ZD. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr Opin Infect Dis. 2008;21(5):500–507. doi:10.1097/QCO.0b013e32830f9397
   PubMed Web of Science ®Google Scholar
• Root-Bernstein R. Innate receptor activation patterns involving TLR and NLR synergisms in COVID-19, ALI/ARDS and sepsis cytokine storms: a review and model making novel predictions and therapeutic suggestions. Int J Mol Sci. 2021;22(4):2108. doi:10.3390/ijms22042108
   PubMed Web of Science ®Google Scholar
• Pedra JH, Cassel SL, Sutterwala FS. Sensing pathogens and danger signals by the inflammasome. Curr Opin Immunol. 2009;21(1):10–16. doi:10.1016/j.coi.2009.01.006
   PubMed Web of Science ®Google Scholar
• Jin C, Flavell RA. Molecular mechanism of NLRP3 inflammasome activation. J Clin Immunol. 2010;30(5):628–631. doi:10.1007/s10875-010-9440-3
   PubMed Web of Science ®Google Scholar
• Platnich JM, Muruve DA. NOD-like receptors and inflammasomes: a review of their canonical and non-canonical signaling pathways. Arch Biochem Biophys. 2019;670:4–14. doi:10.1016/j.abb.2019.02.008
   PubMed Web of Science ®Google Scholar
• Ng J, Hirota SA, Gross O, et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology. 2010;139(2):542–52, 52 e1–3. doi:10.1053/j.gastro.2010.04.005
   Web of Science ®Google Scholar
• Hasegawa M, Kamada N, Jiao Y, Liu MZ, Nunez G, Inohara N. Protective role of commensals against Clostridium difficile infection via an IL-1beta-mediated positive-feedback loop. J Immunol. 2012;189(6):3085–3091. doi:10.4049/jimmunol.1200821
   PubMed Web of Science ®Google Scholar
• Fernandes FP, Leal VNC, Souza de lima D, Reis EC, Pontillo A. Inflammasome genetics and complex diseases: a comprehensive review. Eur J Hum Genet. 2020;28(10):1307–1321. doi:10.1038/s41431-020-0631-y
   PubMed Web of Science ®Google Scholar
• Liu YH, Chang YC, Chen LK, et al. The ATP-P2X7 Signaling Axis Is an Essential Sentinel for Intracellular Clostridium difficile Pathogen-Induced Inflammasome Activation. Front Cell Infect Microbiol. 2018;8:84. doi:10.3389/fcimb.2018.00084
   PubMed Web of Science ®Google Scholar
• Li J, Yan M, Zhang Y, et al. Meta-analysis of the association between NLRP1 polymorphisms and the susceptibility to vitiligo and associated autoimmune diseases. Oncotarget. 2017;8(50):88179–88188. doi:10.18632/oncotarget.21165
   PubMedGoogle Scholar
• Lai Y-H, Tsai B-Y, Hsu C-Y, et al. The role of toll-like receptor-2 in Clostridioides difficile infection: evidence from a mouse model and clinical patients. Front Immunol. 2021;12:548.
   Web of Science ®Google Scholar
• Hung YP, Cia CT, Tsai BY, et al. The first case of severe Clostridium difficile ribotype 027 infection in Taiwan. J Infect. 2015;70(1):98–101. doi:10.1016/j.jinf.2014.08.003
   PubMed Web of Science ®Google Scholar
• Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–1703. doi:10.1056/NEJMoa1012413
   PubMed Web of Science ®Google Scholar
• Sayers EW, Bolton EE, Brister JR, et al. Database resources of the national center for biotechnology information. Nucleic Acids Res. 2022;50(D1):D20–D6. doi:10.1093/nar/gkab1112
   PubMed Web of Science ®Google Scholar
• Schaffler H, Breitruck A. Clostridium difficile - from colonization to infection. Front Microbiol. 2018;9:646. doi:10.3389/fmicb.2018.00646
   PubMed Web of Science ®Google Scholar
• Sun X, Xia Y, Liu Y, et al. Polymorphisms in NLRP1 gene are associated with type 1 diabetes. J Diabetes Res. 2019;2019:7405120. doi:10.1155/2019/7405120
   PubMed Web of Science ®Google Scholar
• Sui J, Li H, Fang Y, et al. NLRP1 gene polymorphism influences gene transcription and is a risk factor for rheumatoid arthritis in han Chinese. Arthritis Rheum. 2012;64(3):647–654. doi:10.1002/art.33370
   PubMedGoogle Scholar
• Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989–2995. doi:10.1001/jama.294.23.2989
   PubMed Web of Science ®Google Scholar
• Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, Kalaitzakis E, Sigurdardottir O, Bjornsson ES. Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case-control study. Eur J Clin Microbiol Infect Dis. 2012;31(10):2601–2610. doi:10.1007/s10096-012-1603-0
   PubMed Web of Science ®Google Scholar
• Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53(1):42–48. doi:10.1093/cid/cir301
   PubMed Web of Science ®Google Scholar
• Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S19–31. doi:10.1086/521859
   PubMed Web of Science ®Google Scholar
• Cho SM, Lee JJ, Yoon HJ. Clinical risk factors for Clostridium difficile-associated diseases. Braz J Infect Dis. 2012;16(3):256–261. doi:10.1590/S1413-86702012000300007
   PubMed Web of Science ®Google Scholar
• Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171(1):33–38. doi:10.1503/cmaj.1040876
   PubMed Web of Science ®Google Scholar
• Wenisch JM, Schmid D, Kuo HW, et al. Hospital-acquired Clostridium difficile infection: determinants for severe disease. Eur J Clin Microbiol Infect Dis. 2012;31(8):1923–1930. doi:10.1007/s10096-011-1522-5
   PubMed Web of Science ®Google Scholar
• Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–1019. doi:10.1038/ajg.2012.108
   PubMed Web of Science ®Google Scholar
• Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–1010. doi:10.1038/ajg.2012.179
   PubMed Web of Science ®Google Scholar
• Lin HJ, Hung YP, Liu HC, et al. Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization. J Microbiol Immunol Infect. 2015;48(2):183–189. doi:10.1016/j.jmii.2013.08.003
   PubMedGoogle Scholar
• Shakov R, Salazar RS, Kagunye SK, Baddoura WJ, DeBari VA. Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am J Infect Control. 2011;39(3):194–198. doi:10.1016/j.ajic.2010.08.017
   PubMed Web of Science ®Google Scholar
• McFarland LV, Clarridge JE, Beneda HW, Raugi GJ. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin Infect Dis. 2007;45(9):1141–1151. doi:10.1086/522187
   PubMed Web of Science ®Google Scholar
• Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029–e44. doi:10.1093/cid/ciab549
   PubMed Web of Science ®Google Scholar